Igand JL. Hydroxymethylglutarylcoenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a reduce in caveolin abundance. Circulation 2001; 103: 1138. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin1 and improves nitric oxidedependent heart price and blood AACS Inhibitors products stress variability in apolipoprotein E/ mice in vivo. Circulation 2003; 107: 24806.[25][45][26][46] [47][27][28][48] [49] [50][29][30][51] [52][31][53] [54][32][33] [34] [35][55] [56][57][36][58][37][59][38][60] [61][39][62] [63][40][41][64][42] [43][65][44]Lipid Raft in Cardiac Well being and Illness [66] Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption from the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 104956. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 could be the main receptor for LDL modified by monocytegenerated reactive nitrogen species. J Clin Invest 2000; 105: 1095108. Diwan A, Dorn GW. Decompensation of cardiac hypertrophy: cellular mechanism and novel therapeutic target. Physiology 2007; 22: 5664. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is just not a necessary compensatory response to brief term pressure overload. Circulation 2000; 101: 28632869. Sano M, Schneider MD. Nonetheless stressed out but undertaking fine: normalization of wall pressure is superfluous to maintain cardiac function in chronic stress overload. Circulation 2002; 105: 810. Koga A, Oka N, Kikuchi T, Miyazaki H, Kato S, Imaizumi T. Adenovirusmediated overexpression of caveolin3 inhibits rat cardiomyocyte hypertrophy. Hypertension 2003; 42: 2139. Fujita T, Otsu K, Oshikawa J, et al. Caveolin3 inhibits growth signal in cardiac myoblasts within a Ca2dependent manner. J Cell Mol Med 2006; 10: 21624. De Souza AP, Cohen AW, Park DS, et al. MR imaging of caveolin genespecific alterations in right ventricular wall thickness. Magn Reson Imaging 2005; 23: 618. Ohsawa Y, Toko H, Katsura M, et al. Overexpression of P104L mutant caveolin3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Hum Mol Genet 2004; 13: 15157. Wunderlich C, Schober K, Lange SA, et al. Disruption of caveolin1 leads to enhanced nitrosative pressure and extreme systolic andRevised: 25 August, 2008 Accepted: 25 August,Current Cardiology Reviews, 2009, Vol. 5, No.[76][67][77] [78][68] [69][79][70] [71][80][72] [73][81] [82][74][83] [84][75]diastolic heart failure. Biochem Biophys Res Commun 2006; 340: 7028. Woodman SE, Park DS, Cohen AW, et al. Caveolin3 knockout mice create a progressive cardiomyopathy and show hyperactivation on the p42/44 MAPK cascade. J Biol Chem 2002; 277: 3898897. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006; 69: 78897. GarciaCardena G, Martasek P, Masters BS, et al. Dissecting the interaction involving nitric oxide synthase (NOS) and caveolin. Functional Chlorobutanol medchemexpress significance from the nos caveolin binding domain in vivo. J Biol Chem 1997; 272: 2543740. Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin1. FASEB J 2007; 21(7): 156574. BallardCroft C, Locklar AC, Kristo G, Lasley RD. Regional myocardial ischemiainduced activation of MAPKs is related with subcellular redistribution of caveolin a.
